Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Cho, Ye Rim ^a   Lim, Ji Hee ^a   Kim, Min Young ^a   Kim, Tae Woo ^a   Hong, Bo Young ^a   Kim, Yong Soo ^a   Chang, Yoon Sik ^a   Kim, Hye Won ^a   Park, Cheol Whee ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MYELIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DISEASE ASSOCIATION; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN PROTEIN INTERACTION; SCHWANN CELL; SCIATIC NERVE; SENSORY DYSFUNCTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ADENOSINE MONOPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIGENS, CD31; BLOOD GLUCOSE; BODY WEIGHT; CELL SURVIVAL; DEOXYGUANOSINE; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FENOFIBRATE; FIBROSIS; HEMOGLOBIN A, GLYCOSYLATED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPIDS; MICE; NEURAL CONDUCTION; PPAR ALPHA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SCHWANN CELLS; SCIATIC NERVE; SCIATIC NEUROPATHY; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84894825487     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083204     Document Type: Article

References (44)

1. Sima AA, Thomas PK, Ishii D, Vinik A (1997) Diabetic neuropathies. Diabetologia 40: B74-B77. (Pubitemid 27428283)
2. Greene DA, Stevens MJ, Feldman EL (1999) Diabetic neuropathy: scope of syndrome. Am J Med 107: 2S-8S.
3. Diabetes Control and Complication Trial (DCCT) Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Eng J Med 329: 977-986.
4. Cameron NE, Eaton SE, Cotter MA, Tesfaye S (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44: 1973-1988. (Pubitemid 33124042)
5. Van Dam PS (2002) Oxidative stress and diabetic nephropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Met Res Rev 18:176- 184.
6. Green DA, Lattimer SA, Sima AA (1988) Perspectives in diabetes: are disturbances of sorbitol phosphoinositide and Na + -K + ATPase regulation involved in pathogenesis of diabetic nephropathy? Diabetes 37: 688-693. (Pubitemid 19043173)
7. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, et al. (1996) The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2: 703-707. (Pubitemid 26191962)
8. Stevens EJ, Carrington AL, Tomlinson DR (1994) Nerve ischemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models. Diabetologia 36: 1266-1274.
9. Young MJ, Veves A, Walker MG, Boultron AJ (1992) Correlation between nerve conduction and tissue oxygenation in diabetes patients: further clues to the aetiology of diabetic neuropathy? Diabetologia 35: 1146-1150.
10. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, et al. (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimating of severity, and treatments. Diabetes Care 33: 2285-2293.
11. Britland ST, Sharma AK, Duguid IG, Thomas PK (1985) Ultrastructural observations on myelinated fibers in the tibial nerve of steptozotocin-diabetic rats: effect of insulin treatment. Life Support Syst Suppl 1: 525-529.
12. Jakobsen J (1976) Axonal dwindling in early experimental diabetes. I. A study of cross sectional nerves. Diabetologia 12:539-546.
13. Behse F, Buchthal F, Carlsen F (1977) Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosug Psyciatry. 40: 1072-1082. (Pubitemid 8261758)
14. Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280: C1358-C1366. (Pubitemid 32553190)
15. Nissen NN, Polverini PJ, Koch AE, Vollin MV, Gamelli RL, et al. (1998) Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol. 152: 1445-1452. (Pubitemid 28275003)
16. Schratzberger P, Walter DH, Rittig K, Bahlmann FH, Pola R, et al. (2001) Reversal experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 107: 1083-1092. (Pubitemid 32422905)
17. Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19: 5731-5740. (Pubitemid 29327910)
18. Ropper AH, Gorson KC, Gooch CL, Weinberg DH, Pieczek A, et al. (2009) Vascular endothelial growth factor gene transfer in diabetic polyneuropathy: a randomized and double-blinded trial. Ann Neurol 65: 386-393.
19. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, et al. (2008) HIFindependent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1a. Nature. 451: 1008-1012. (Pubitemid 351301733)
20. Finck BN, Kelly DP (2007) Peroxisome proliferator-activated receptor c coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 115: 2540-2548. (Pubitemid 46763228)
21. Davis TME, Yeap BB, Davis WA, Bruce DG (2008) Lipid-lowering therapy and peripheral sensory neuropathy. Diabetologia 51: 562-566.
22. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, et al. (2006) Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor a. Diabetes 55: 885-893.
23. Park CW, Kim HW, Lim JH, Yoo KD, Chung S, et al. (2009) Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice. Diabetes 58: 2666-2676.
24. Biscetti E, Gaetani E, Flex A, Aprahamian T, Hopkins T, et al. (2008) Selective activation of peroxisome proliferator-activated receptor (PPAR)a and PPARc induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57: 1394-1404.
25. Okayasu T, Tomizawa A, Suzuki K, Manaka K, Hattori Y (2008) PPARa activators upregulate eNOS activity and inhibit cytokine-induced NF-kB activation through AMP-activated protein kinase activation. Life Sci 82: 884- 891.
26. Wenz T, Diaz F, Spiegelman BM, Moraes CT (2008) Activation of the PPAR/ PGC-1alpha prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 8: 249-256.
27. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP (2007) Insulinresistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-a/PGC-1a gene regulatory pathway. Circulation 115: 909-917. (Pubitemid 46294731)
28. Ferrara N, Karver-Moore K, Chen H, Dowd M, Lu L, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442. (Pubitemid 26102720)
29. Bae DG, Kim TD, Yoon WH, Chae CB (2005) Anti-Flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin Cancer Res 11: 2651-2661.
30. Binetryt-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, et al. (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO journal 19: 1525-1533. (Pubitemid 30182160)
31. Starzec A, Vassy R, Martin A, Lecouvey M, Benedetto MD, et al. (2006) Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci 79: 2370-2381. (Pubitemid 44772930)
32. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63. (Pubitemid 24238751)
33. Fioretto BI, Dodson PM, Ziegler D, Robensen RS (2010) Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 6: 19-25.
34. Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32: 101-1903.
35. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, et al. (2009) Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58: 1634-1640.
36. Kilo S, Berghoff M, Hilz M, Freeman R (2002) Neural and endothelial control of the microcirculation in diabetic peripheral neuropathy. Neurology 54: 1246- 1252.
37. Bento-Abreu A, Tabernero A, Medina JM (2007) Peroxisome proliferatoractivated receptor-a is required for the neurotropic effect of oleic acid in neurons. J Neurochem 103: 871-881. (Pubitemid 47568723)
38. Xu J,Racke MK, Drew PD (2007) Peroxisome proliferator-activated receptor a agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J Neurochem 103: 1801-1810. (Pubitemid 350126611)
39. Fissithaler B, Fleming I (2009) Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 105: 1114-127.
40. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J (1999) PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131. (Pubitemid 29289077)
41. Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K (2011) Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism 60: 513-522.
42. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, et al. (1998) Vascular endothelial growth factor regulates endothelial cell survival though the phosphatidylinositol 39-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 273: 30336-30343. (Pubitemid 28545503)
43. Alon T, Hemo I, Itin A, Peer J, Stone J, et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024-1928.
44. Iversen N, Krsutrup P, Rasmussen HN, Rasmussen UF, Saltin B, et al. (2011) Mitochondrial biogenesis and angiogenesis in skeletal muscle of the elderly. Exp Gerontol 46: 670-678.